High-risk prostate cancer-Classification and therapy

Nature Reviews Clinical Oncology

Volumn 11, Issue 6, 2014, Pages 308-323

  Chang, Albert J ^a   Autio, Karen A ^b   Roach, MacK ^a   Scher, Howard I ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GOSERELIN;

ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CANCER CLASSIFICATION; CANCER HORMONE THERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER RISK; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HIGH RISK POPULATION; HUMAN; LYMPH NODE DISSECTION; OVERALL SURVIVAL; PELVIS LYMPH NODE; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; REVIEW;

HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84902013335     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2014.68     Document Type: Review

References (142)

1. Scher, H. I. & Heller, G. Clinical states in prostate cancer: toward a dynamic model of disease progression. Urology 55, 323-327 (2000).
2. Siegel, R., Naishadham, D. & Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin. 63, 11-30 (2013).
3. Cooperberg, M. R., Broering, J. M. & Carroll, P. R. Time trends and local variation in primary treatment of localized prostate cancer. J. Clin. Oncol. 28, 1117-1123 (2010).
4. D'Amico, A. V. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280, 969-974 (1998).
5. Thompson, I. et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J. Urol. 177, 2106-2131 (2007).
6. Roach, M. et al. Four prognostic groups predict long-term survival from prostate cancer following radiotherapy alone on Radiation Therapy Oncology Group clinical trials. Int. J. Radiat. Oncol. Biol. Phys. 47, 609-615 (2000).
7. Roach, M. 3rd et al. Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials. J. Urol. 176, S16-S20 (2006).
8. Huang, J. et al. Percentage of positive biopsy cores: a better risk stratification model for prostate cancer? Int. J. Radiat. Oncol. Biol. Phys. 83, 1141-1148 (2012).
9. Cooperberg, M. R. et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J. Urol. 173, 1938-1942 (2005).
10. Cooperberg, M. R., Broering, J. M. & Carroll, P. R. Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J. Natl Cancer Inst. 101, 878-887 (2009).
11. Kattan, M. W., Eastham, J. A., Stapleton, A. M., Wheeler, T. M. & Scardino, P. T. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J. Natl Cancer Inst. 90, 766-771 (1998).
12. Yossepowitch, O. et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J. Urol. 178, 493-499 (2007).
13. Gosselaar, C., Kranse, R., Roobol, M. J., Roemeling, S. & Schroder, F. H. The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate 68, 985-993 (2008).
14. American Joint Committee on Cancer. AJCC Cancer Staging Manual, 7th edn (Springer, New York, 2011).
15. Yakar, D. et al. Predictive value of MRI in the localization, staging, volume estimation, assessment of aggressiveness, and guidance of radiotherapy and biopsies in prostate cancer. J. Magn. Reson. Imaging 35, 20-31 (2012).
16. Zhang, J. Q., Loughlin, K. R., Zou, K. H., Haker, S. & Tempany, C. M. Role of endorectal coil magnetic resonance imaging in treatment of patients with prostate cancer and in determining radical prostatectomy surgical margin status: report of a single surgeon's practice. Urology 69, 1134-1137 (2007).
17. Peng, Y. et al. Quantitative analysis of multiparametric prostate MR images: differentiation between prostate cancer and normal tissue and correlation with Gleason score-a computer-aided diagnosis development study. Radiology 267, 787-796 (2013).
18. Puech, P. et al. Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy-prospective multicenter study. Radiology 268, 461-469 (2013).
19. Tiwari, P., Kurhanewicz, J. & Madabhushi, A. Multi-kernel graph embedding for detection, Gleason grading of prostate cancer via MRI/MRS. Med. Image Anal. 17, 219-235 (2013).
20. Cooperberg, M. R. et al. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. J. Clin. Oncol. 31, 1428-1434 (2013).
21. Ding, Z. et al. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 470, 269-273 (2011).
22. Roach, M. 3rd, Waldman, F. & Pollack, A. Predictive models in external beam radiotherapy for clinically localized prostate cancer. Cancer 115, 3112-3120 (2009).
23. Durand, X. et al. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int. 110, 43-49 (2012).
24. Lin, D. W. et al. Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin. Cancer Res. 19, 2442-2450 (2013).
25. Shore, N. et al. Clinical utility of a biopsy-based cell cycle gene expression assay in localized prostate cancer. Curr. Med. Res. Opin. 30, 547-553 (2014).
26. Knezevic, D. et al. Analytical validation of the Oncotype DX prostate cancer assay-a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics 14, 690 (2013).
27. Donovan, M. J. & Cordon-Cardo, C. Predicting high-risk disease using tissue biomarkers. Curr. Opin. Urol. 23, 245-251 (2013).
28. Bolla, M. et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360, 103-106 (2002).
29. Pilepich, M. V. et al. Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma-long-term results of phase III RTOG 85-31 Int. J. Radiat. Oncol. Biol. Phys. 61, 1285-1290 (2005).
30. Beckendorf, V. et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int. J. Radiat. Oncol. Biol. Phys. 80, 1056-1063 (2011).
31. Creak, A. et al. Randomised pilot study of dose escalation using conformal radiotherapy in prostate cancer: long-term follow-up. Br. J. Cancer 109, 651-657 (2013).
32. Kuban, D. A. et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease? Int. J. Radiat. Oncol. Biol. Phys. 79, 1310-1317 (2011).
33. Peeters, S. T. et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J. Clin. Oncol. 24, 1990-1996 (2006).
34. Roach, M. 3rd. Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both? Strahlenther. Onkol. 183, 26-28 (2007).
35. Widmark, A. et al. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 373, 301-308 (2009).
36. Warde, P. et al. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: a randomised, phase 3 trial. Lancet 378, 2104-2111 (2011).
37. Bechis, S. K., Carroll, P. R. & Cooperberg, M. R. Impact of age at diagnosis on prostate cancer treatment and survival. J. Clin. Oncol. 29, 235-241 (2011).
38. Lu-Yao, G. L. et al. Outcomes of localized prostate cancer following conservative management. JAMA 302, 1202-1209 (2009).
39. Roach, M. 3rd et al. Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. J. Clin. Oncol. 26, 585-591 (2008).
40. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00936390 (2014).
41. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01368588 (2013).
42. Nichol, A. M., Warde, P. & Bristow, R. G. Optimal treatment of intermediate-risk prostate carcinoma with radiotherapy: clinical and translational issues. Cancer 104, 891-905 (2005).
43. Bolla, M. et al. Duration of androgen suppression in the treatment of prostate cancer. N. Engl. J. Med. 360, 2516-2527 (2009).
44. Horwitz, E. M. et al. Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. J. Clin. Oncol. 26, 2497-2504 (2008).
45. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00223171 (2013).
46. Nabid, A. et al. Duration of androgen deprivation therapy in high-risk prostate cancer: a randomized trial [abstract LBA4510]. J. Clin. Oncol. 31 (Suppl.), (2013).
47. Ahmadi, H. & Daneshmand, S. Androgen deprivation therapy: evidence-based management of side effects. BJU Int. 111, 543-548 (2013).
48. Cormie, P. et al. Can supervised exercise prevent treatment toxicity in prostate cancer patients initiating androgen deprivation therapy: a randomised controlled trial. BJU Int. http://dx.doi.org/10.1111/bju.12646.
49. Gardner, J. R., Livingston, P. M. & Fraser, S. F. Effects of exercise on treatment-related adverse effects for patients with prostate cancer receiving androgen-deprivation therapy: a systematic review. J. Clin. Oncol. 32, 335-346 (2014).
50. Saylor, P. J., Keating, N. L. & Smith, M. R. Prostate cancer survivorship: prevention and treatment of the adverse effects of androgen deprivation therapy. J. Gen. Intern. Med. 24 (Suppl. 2), S389-S394 (2009).
51. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995-2005 (2011).
52. de Bono, J. S. et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376, 1147-1154 (2010).
53. Fizazi, K. et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 13, 983-992 (2012).
54. Kantoff, P. W. et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N. Engl. J. Med. 363, 411-422 (2010).
55. Parker, C. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N. Engl. J. Med. 369, 213-223 (2013).
56. Ryan, C. J. et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N. Engl. J. Med. 368, 138-148 (2013).
57. Scher, H. I. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367, 1187-1197 (2012).
58. Zelefsky, M. J. et al. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 41, 491-500 (1998).
59. Levegrün, S. et al. Risk group dependence of dose-response for biopsy outcome after three-dimensional conformal radiation therapy of prostate cancer. Radiother. Oncol. 63, 11-26 (2002).
60. Dearnaley, D. P. et al. Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial. Lancet Oncol. 8, 475-487 (2007).
61. Sathya, J. R. et al. Randomized trial comparing iridium implant plus external-beam radiation therapy with external-beam radiation therapy alone in node-negative locally advanced cancer of the prostate. J. Clin. Oncol. 23, 1192-1199 (2005).
62. Zietman, A. L. et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from Proton Radiation Oncology Group/American College of Radiology 95-09. J. Clin. Oncol. 28, 1106-1111 (2010).
63. Zelefsky, M. J., Reuter, V. E., Fuks, Z., Scardino, P. & Shippy, A. Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J. Urol. 179, 1368-1373 (2008).
64. Fang, L. C. et al. High-risk prostate cancer with Gleason score 8-10 and PSA level ≤15 ng/mL treated with permanent interstitial brachytherapy. Int. J. Radiat. Oncol. Biol. Phys. 81, 992-996 (2011).
65. Vargas, C. et al. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate-and high-risk features. Prostate Cancer Prostatic Dis. 9, 245-253 (2006).
66. D'Amico, A. V. et al. Risk of death from prostate cancer after brachytherapy alone or with radiation, androgen suppression therapy, or both in men with high-risk disease. J. Clin. Oncol. 27, 3923-3928 (2009).
67. Stephenson, A. J. et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J. Clin. Oncol. 27, 4300-4305 (2009).
68. Eggener, S. E. et al. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J. Urol. 185, 869-875 (2011).
69. Spahn, M. et al. Outcome predictors of radical prostatectomy in patients with prostate-specific antigen greater than 20 ng/ml: a European multi-institutional study of 712 patients. Eur. Urol. 58, 1-7 (2010).
70. Zwergel, U. et al. Outcome of prostate cancer patients with initial PSA > or = 20 ng/ml undergoing radical prostatectomy. Eur. Urol. 52, 1058-1065 (2007).
71. Klein, E. A. et al. Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories. J. Urol. 179, 2212-2216 (2008).
72. Begg, C. B. et al. Variations in morbidity after radical prostatectomy. N. Engl. J. Med. 346, 1138-1144 (2002).
73. Valicenti, R. K. et al. Adjuvant and salvage radiation therapy after prostatectomy: American Society for Radiation Oncology/American Urological Association guidelines. Int. J. Radiat. Oncol. Biol. Phys. 86, 822-828 (2013).
74. Thompson, I. M. et al. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J. Urol. 190, 441-449 (2013).
75. Boorjian, S. A. et al. Long-term survival after radical prostatectomy versus external-beam radiotherapy for patients with high-risk prostate cancer. Cancer 117, 2883-2891 (2011).
76. Briganti, A. et al. Identifying the best candidate for radical prostatectomy among patients with high-risk prostate cancer. Eur. Urol. 61, 584-592 (2012).
77. Ward, J. F., Slezak, J. M., Blute, M. L., Bergstralh, E. J. & Zincke, H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome. BJU Int. 95, 751-756 (2005).
78. Yossepowitch, O. et al. Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy. Eur. Urol. 53, 950-959 (2008).
79. Bill-Axelson, A. et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 364, 1708-1717 (2011).
80. Wilt, T. J. et al. Radical prostatectomy versus observation for localized prostate cancer. N. Engl. J. Med. 367, 203-213 (2012).
81. Briganti, A. et al. Pelvic lymph node dissection in prostate cancer. Eur. Urol. 55, 1251-1265 (2009).
82. Stone, N. N., Stock, R. G. & Unger, P. Laparoscopic pelvic lymph node dissection for prostate cancer: comparison of the extended and modified techniques. J. Urol. 158, 1891-1894 (1997).
83. Briganti, A. et al. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. Eur. Urol. 50, 1006-1013 (2006).
84. Bader, P., Burkhard, F. C., Markwalder, R. & Studer, U. E. Is a limited lymph node dissection an adequate staging procedure for prostate cancer? J. Urol. 168, 514-518 (2002).
85. Keller, H., Lehmann, J. & Beier, J. Radical perineal prostatectomy and simultaneous extended pelvic lymph node dissection via the same incision. Eur. Urol. 52, 384-388 (2007).
86. Wyler, S. F. et al. Laparoscopic extended pelvic lymph node dissection for high-risk prostate cancer. Urology 68, 883-887 (2006).
87. Liss, M. A. et al. Outcomes and complications of pelvic lymph node dissection during robotic-assisted radical prostatectomy. World J. Urol. 31, 481-488 (2013).
88. World Health Organization. International Clinical Trials Registry Program; German Clinical Trials Register [online], http://apps.who.int/ trialsearch/trial.aspx?trialid=DRKS00003256 (2014).
89. Feifer, A. H. et al. Temporal trends and predictors of pelvic lymph node dissection in open or minimally invasive radical prostatectomy. Cancer 117, 3933-3942 (2011).
90. Gandaglia, G. et al. The impact of robot-assisted radical prostatectomy on the use and extent of pelvic lymph node dissection in the "post-dissemination" period. Eur. J. Surg. Oncol. http://dx.doi.org/ 10.1016/j.ejso.2013.12.016.
91. Yuh, B. et al. The role of robot-assisted radical prostatectomy and pelvic lymph node dissection in the management of high-risk prostate cancer: A systematic review. Eur. Urol. 65, 918-927 (2014).
92. Weingartner, K. et al. Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic. J. Urol. 156, 1969-1971 (1996).
93. Heidenreich, A., Ohlmann, C. H. & Polyakov, S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur. Urol. 52, 29-37 (2007).
94. Wagner, M., Sokoloff, M. & Daneshmand, S. The role of pelvic lymphadenectomy for prostate cancer-therapeutic? J. Urol. 179, 408-413 (2008).
95. Touijer, K. A., Mazzola, C. R., Sjoberg, D. D., Scardino, P. T. & Eastham, J. A. Long-term outcomes of patients with lymph node metastasis treated with radical prostatectomy without adjuvant androgen-deprivation therapy. Eur. Urol. 65, 20-25 (2014).
96. Engel, J. et al. Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer. Eur. Urol. 57, 754-761 (2010).
97. Ji, J., Yuan, H., Wang, L. & Hou, J. Is the impact of the extent of lymphadenectomy in radical prostatectomy related to the disease risk? A single center prospective study. J. Surg. Res. 178, 779-784 (2012).
98. Bolla, M. et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 366, 572-578 (2005).
99. Bolla, M. et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 380, 2018-2027 (2012).
100. Thompson, I. M. et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J. Urol. 181, 956-962 (2009).
101. Wiegel, T. et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J. Clin. Oncol. 27, 2924-2930 (2009).
102. Thompson, I. M. Jr et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 296, 2329-2335 (2006).
103. Moinpour, C. M. et al. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy. J. Clin. Oncol. 26, 112-120 (2008).
104. Briganti, A. et al. Early salvage radiation therapy does not compromise cancer control in patients with pT3N0 prostate cancer after radical prostatectomy: results of a match-controlled multi-institutional analysis. Eur. Urol. 62, 472-487 (2012).
105. Nam, R. K. et al. Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study. Lancet Oncol. 15, 223-231 (2014).
106. Bhojani, N. et al. The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int. J. Radiat. Oncol. Biol. Phys. 76, 342-348 (2010).
107. Bostrom, P. J. & Soloway, M. S. Secondary cancer after radiotherapy for prostate cancer: should we be more aware of the risk? Eur. Urol. 52, 973-982 (2007).
108. Moon, K., Stukenborg, G. J., Keim, J. & Theodorescu, D. Cancer incidence after localized therapy for prostate cancer. Cancer 107, 991-998 (2006).
109. Stephenson, A. J. et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J. Clin. Oncol. 25, 2035-2041 (2007).
110. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00541047 (2012).
111. Current Controlled Trials Ltd. International Standard Randomised Controlled Trial Number Register [online], http://www.controlled-trials.com/ ISRCTN40814031/ISRCTN40814031 (2011).
112. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00860652 (2013).
113. Keating, N. L., O'Malley, A. J. & Smith, M. R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J. Clin. Oncol. 24, 4448-4456 (2006).
114. Nguyen, P. L. et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. JAMA 306, 2359-2366 (2011).
115. Punnen, S., Cooperberg, M. R., Sadetsky, N. & Carroll, P. R. Androgen deprivation therapy and cardiovascular risk. J. Clin. Oncol. 29, 3510-3516 (2011).
116. Arcangeli, G. et al. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 75, 975-982 (2009).
117. Zelefsky, M. J. et al. Metastasis after radical prostatectomy or external beam radiotherapy for patients with clinically localized prostate cancer: a comparison of clinical cohorts adjusted for case mix. J. Clin. Oncol. 28, 1508-1513 (2010).
118. Zelefsky, M. J. et al. Predicting biochemical tumor control after brachytherapy for clinically localized prostate cancer: The Memorial Sloan-Kettering Cancer Center experience. Brachytherapy 11, 245-249 (2012).
119. Kattan, M. W. et al. Pretreatment nomogram that predicts 5-year probability of metastasis following three-dimensional conformal radiation therapy for localized prostate cancer. J. Clin. Oncol. 21, 4568-4571 (2003).
120. Hsu, C. C. et al. Feasibility of MR imaging/MR spectroscopy-planned focal partial salvage permanent prostate implant (PPI) for localized recurrence after initial PPI for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 85, 370-377 (2013).
121. Chen, C. P. et al. Salvage HDR brachytherapy for recurrent prostate cancer after previous definitive radiation therapy: 5-year outcomes. Int. J. Radiat. Oncol. Biol. Phys. 86, 324-329 (2013).
122. Giordano, S. H. et al. Limits of observational data in determining outcomes from cancer therapy. Cancer 112, 2456-2466 (2008).
123. Eifler, J. B. et al. Causes of death after radical prostatectomy at a large tertiary center. J. Urol. 188, 798-801 (2012).
124. Lane, J. A. et al. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur. J. Cancer 46, 3095-3101 (2010).
125. Jang, T. L. et al. Physician visits prior to treatment for clinically localized prostate cancer. Arch. Intern. Med. 170, 440-450 (2010).
126. Sommers, B. D. et al. Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer 113, 2058-2067 (2008).
127. Bastian, P. J. et al. High-risk prostate cancer: from definition to contemporary management. Eur. Urol. 61, 1096-1106 (2012).
128. Bellmunt, J. et al. Advances in the management of high-risk localised and metastatic prostate cancer. BJU Int. 109 (Suppl. 2), 8-13 (2012).
129. Gomella, L. G. et al. Enhancing prostate cancer care through the multidisciplinary clinic approach: a 15-year experience. J. Oncol. Pract. 6, e5-e10 (2010).
130. Bianco, F. J. Jr, Scardino, P. T. & Eastham, J. A. Radical prostatectomy: long-term cancer control and recovery of sexual and urinary function ("trifecta"). Urology 66, 83-94 (2005).
131. Jacobs, E. F., Boris, R. & Masterson, T. A. Advances in robotic-assisted radical prostatectomy over time. Prostate Cancer 2013, 902686 (2013).
132. Turpen, R., Atalah, H. & Su, L. M. Technical advances in robot-assisted laparoscopic radical prostatectomy. Ther. Adv. Urol. 1, 251-258 (2009).
133. Taplin, M.-E. et al. Effect of neoadjuvant abiraterone acetate (AA) plus leuprolide acetate (LHRHa) on PSA, pathological complete response (pCR), and near pCR in localized high-risk prostate cancer (LHRPC): Results of a randomized phase II study [abstract]. J. Clin. Oncol. 30 (Suppl.), a4521 (2012).
134. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00924469 (2013).
135. Tollefson, M. K. et al. A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer. [Abstract, 168], ASCO Genitourinary Cancers Symposium, March 5-7, San Francisco, CA. http://meetinglibrary.asco.org/content/30897.73 (2010).
136. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00430183 (2013).
137. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT02023463 (2014).
138. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT01546987 (2014).
139. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00651326 (2012).
140. US National Library of Medicine. ClinicalTrials.gov [online], http://clinicaltrials.gov/show/NCT00116142 (2013).
141. Heidenreich, A. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur. Urol. 59, 61-71 (2011).
142. Cooperberg, M. R., Hilton, J. F. & Carroll, P. R. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. Cancer 117, 5039-5046 (2011).